ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
Copyright: © 2017 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
METHOD
Technologies of Cell Immunotherapy in Treatment of Cancer Patients
About authors
1 Department of Positron Emission Tomography,
N. N. Blokhin Russian Cancer Research Center, Moscow, Russia
2 Pirogov Russian National Research Medical University, Moscow, Russia
3 Sechenov First Moscow State Medical University, Moscow, Russia
Correspondence should be addressed:
Kashirskoe sh., d. 23, Moscow, Russia, 115478; ur.liam@votit-sk
Received: 2014-02-06
Accepted: 2014-02-20
Published online: 2017-01-05
|
The study evaluated clinical efficacy and safety of the use of cells antitumor immunotherapy methods — vaccines based on autologic dendritic and allogenic LAK-cells in combination with recombinant interleukin-2 (IL-2). The clinical study involved cancer patients with skin melanoma of grades III-IV and patients with metastatic effusions resistant to systemic chemotherapy. The data led to the conclusion of safety, immune competence and reasonable effectiveness of DC-based vaccines in therapeutic and prophylactic schemes in patients with skin melanoma. The results showed that intra-cavity IL-2/LAK-immunotherapy was highly effective and well tolerated in treatment of patients with metastatic effusions.
Keywords: cell Immunotherapy, dendritic cells, interleukin-2, LAK-cells